Rifagut 550 mg (Tablet)
Medicine Details
| Category | Details |
|---|---|
| Generic | Rifaximin |
| Company | Opsonin pharma ltd |
| Also available as |
Indications
- Treatment of traveler's diarrhea by noninvasive strains of E. coli
- Reduction in risk of overt hepatic encephalopathy
- Bacterial overgrowth of irritable bowel syndrome
Pharmacology
Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic. It inhibits bacterial RNA synthesis by its action on the beta-subunit of the DNA-dependent RNA polymerase.
Dosage & Administration
- Traveler's Diarrhea: 200 mg 3 times daily for 3 days (patients ≥12 years of age)
- Hepatic Encephalopathy: 550 mg 2 times daily (patients ≥18 years of age)
- Bacterial overgrowth of irritable bowel syndrome:
- 400 mg 3 times daily for 10 days
- 550 mg 3 times daily for 14 days
- Administration: Can be taken with or without food
Interaction
Rifagut induces CYP3A4 in vitro. However, at the recommended dosing regimen, it is not expected to induce CYP3A4 in patients with normal liver function.
Contraindications
Hypersensitivity to Rifaximin or to any of the rifamycin antimicrobial agents, or any components of this product
Side Effects
- Flatulence
- Headache
- Abdominal pain
- Rectal tenesmus
- Defecation urgency
- Nausea
- Constipation
- Pyrexia
- Vomiting
- Anaphylaxis
- Angioneurotic edema
- Exfoliative dermatitis
Pregnancy & Lactation
Pregnancy category C. Excretion in human milk is unknown.
Precautions & Warnings
- Not effective in patients with diarrhea complicated by fever and/or blood in the stools
- Discontinue if diarrhea symptoms worsen or persist for more than 24-48 hours
- Consider alternative antibiotic therapy
- Consider Pseudomembranous colitis in patients with diarrhea after antibacterial administration
Use in Special Populations
- Renal Impairment: Pharmacokinetics not studied in patients with impaired renal function
- Hepatic Impairment: Systemic exposure elevated in patients with hepatic impairment compared to healthy subjects
Overdose Effects
No specific information available on the treatment of overdose with Rifagut. Discontinue, treat symptomatically, and institute supportive measures as required.
Therapeutic Class
4-Quinolone preparations
Storage Conditions
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.